Table 5.
Literature on cTACE versus DEB-TACE
| Reference | Patients (n) | Median survival (mo)
|
Tumor response (%)
|
Time to progression (mo)
|
Adverse events | |||
|---|---|---|---|---|---|---|---|---|
| cTACE | DEB-TACE | cTACE | DEB-TACE | cTACE | DEB-TACE | |||
| Facciorusso et al22 | 249 | 39.0 | 32.0 | 85.3 | 74.8 | 17.0 | 11.0 | No differences |
| Golfieri et al11 | 177 | 28.0 | 29.0 | 74.1 | 74.7 | 9.0 | 9.0 | Less pain after DEB-TACE |
| Kloeckner et al21 | 250 | 13.6 | 12.3 | n/a | n/a | n/a | n/a | No differences |
| Song et al13 | 129 | 24.7 | 32.2 | 49.4 | 81.6 | 7.6 | 11.7 | No differences |
| Dhanasekaran et al12 | 71 | 3.8 | 13.4 | n/a | n/a | n/a | n/a | No difference in mortality |
Abbreviations: cTACE, conventional transarterial chemoembolization; DEB-TACE, transarterial chemoembolization with drug-eluting beads; mo, months; n/a, not applicable.